The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation

References

• Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med. 2004;255: 332–43.
   Google Scholar
• Wen L, Huang JK, Johnson BH, Reeck GR. A human placental cDNA clone that encodes nonhistone chromosomal protein HMG-1. Nucleic Acids Res. 1989;17:1197–214.
   PubMed Web of Science ®Google Scholar
• Bianchi ME, Falciola L, Ferrari S, Lilley DM. The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins. EMGO J. 1992;11:1055–63.
   PubMed Web of Science ®Google Scholar
• Falciola L, Spada F, Calogero S, Langst G, Voit R, Grummt I, et al. High mobility group 1 protein is not stably associated with the chromosomes of somatic cells. J Cell Biol. 1997;137:19–26.
   PubMed Web of Science ®Google Scholar
• Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M, Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 1998;12:462–72.
   PubMed Web of Science ®Google Scholar
• Agresti A, Lupo R, Bianchi ME, Muller S. HMGB1 interacts differently with members of the Rel family of transcription fac-tors. Biochem Biophys Res Commun. 2003;302:421–6.
   PubMed Web of Science ®Google Scholar
• Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani R, Bianchi ME, et al. High-mobility group chromatin proteins! and 2 functionally interact with steroid hormone recep-tors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol. 1998;18:4471–87.
   PubMed Web of Science ®Google Scholar
• Calogero S, Grassi F, Aguzzi A, Voigtländer T, Ferrier P, Ferrari S, et al. The lack of chromosomal protein Hmg 1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet. 1999;22: 276–80.
   Google Scholar
• Daston MM, Ratner N. Expression of P30, a protein with adhesive properties, in Schwann cells and neurons of the developing and regenerating peripheral nerve. J Cell Biol. 1991;112:1229–39.
   PubMed Web of Science ®Google Scholar
• Debryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganiza-tion in rat smooth muscle cells. J Cell Biol. 2001;152:1197–206.
   PubMed Web of Science ®Google Scholar
• Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signaling suppresses tumor growth. Nature. 2000;405:354–60.
   PubMed Web of Science ®Google Scholar
• Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom 0, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human mono-cytes. J Exp Med. 2000;192: 565–70.
   Google Scholar
• Zimmermann K, Volkel D, Pable S, Lindner T, Kramberger F, Bahrami S, et al. Native versus recombinant high-mobility group B1 proteins: functional activity in vitro. Inflammation. 2004;28:221–9.
   PubMed Web of Science ®Google Scholar
• Wang H, Visnubhakat JM, Bloom 0, Zhang M, Ombrellino M, Sama A, Tracey KJ. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery. 1999;126: 389–92.
   Google Scholar
• Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala JME, Erlandsson-Harris H, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med. 2003;254: 375–85.
   Google Scholar
• Mullins GE, Sunden-Cullberg J, Johansson AS, Rouhiainen A, Errlandsson-Harris H, et al. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand J Immunol. 2004;60:566–73.
   PubMed Web of Science ®Google Scholar
• Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Thl polarization. J Immunol. 2004;173:307–13.
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol. 2007;81:59–66.
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2004;83:876–86.
   Web of Science ®Google Scholar
• Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B et al. RAGE is the major receptor for the proinflam-matory activity of HMGB1 in rodent macrophages. Scand J Immunol. 2005;61:1–9.
   PubMed Web of Science ®Google Scholar
• Park JS, Svetkauskaite D, He Q, Kim HY, Strassheim D, Ishizaka A et al. Involvement of toll-like receptors 2 and 4 in the cellular activation by high mobility group box 1 protein. J Biol Chem. 2004;279:7370–7.
   PubMed Web of Science ®Google Scholar
• Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim Jy, Strassheim D, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol. 2006;290:C917–24.
   PubMed Web of Science ®Google Scholar
• Gardella S, Andrei C, Ferrera D, Lotti LV, Tonisi MR, Bianchi ME et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002;10:995–1001.
   Web of Science ®Google Scholar
• Youn JH, Shin JS. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol. 2006;177:7889–97.
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418: 191–5.
   Google Scholar
• Bell CW, Jiang W, Reich CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. J Physiol Cell Physiol. 2006;291:C1318–25.
   PubMed Web of Science ®Google Scholar
• Wang H, Bloom 0, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285: 248–51.
   Google Scholar
• Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Ta-naka M et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury, Am J Respir Crit Care Med. 2004;170:1306–10.
   Google Scholar
• Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13:2836–48.
   PubMed Web of Science ®Google Scholar
• Taira T, Matsuyama W, Mitsuyama H, Kawahara KI, Higa-shimoto I, Maruyama I et al. Increased serum high mobility box-1 level in Churg-Strauss syndrome. Clin Exp Immunol. 2007;148:241–7.
   PubMed Web of Science ®Google Scholar
• Ek M, Popovic K, Harris HE, Naucler CS, Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 2006;54: 2289–94.
   Google Scholar
• Sobajima J, Ozaki S, Uesugi H, Osakada F, Shirakawa H, Yos-hida M et al. Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC). Clin Exp Immunol. 1998;111:402–7.
   PubMed Web of Science ®Google Scholar
• Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 2002;46:2598–603.
   PubMed Web of Science ®Google Scholar
• Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003;48:971–81.
   PubMed Web of Science ®Google Scholar
• Pullertis R, Jonsson IM, Verdrengh M, Bokarewa M, Andersson U, Erlandsson-Harris H et al. High mobility group box chromo-somal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum. 2003;48:1693–700.
   PubMed Web of Science ®Google Scholar
• Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 2003;48:2052–8.
   PubMed Web of Science ®Google Scholar
• Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M, Patel NB et al. Cholinergic anti-inflammatory pathway activity and high mobility group box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med. 2007;13:210–5.
   PubMed Web of Science ®Google Scholar
• Santoro P, De Andrea M, Migliaretti G, Trapani C, Landolfo S, Gariglio M. High prevalence of autoantibodies against the nuclear high mobility group (HMG) protein SSRP1 in sera from patients with systemic lupus erythematosus, but not other rheu-matic diseases. J Rheumatol. 2002;29:90–3.
   PubMed Web of Science ®Google Scholar
• Wittemann B, Neuer G, Michels H, Truckenbrodt H, Bautz FA. Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1990;33: 1378–83.
   Google Scholar
• Rosenberg AM, Cordeiro DM. Relationship between sex and antibodies to high mobility group proteins 1 and 2 in juvenile idiopathic arthritis. J Rheumatol. 2000;27:2489–93.
   PubMed Web of Science ®Google Scholar
• Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Warhren-Herlenius M et al. Increased expression of the novel proinflam-matory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum. 2005;52:3639–45.
   PubMed Web of Science ®Google Scholar
• Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8:487–96.
   PubMed Web of Science ®Google Scholar
• Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK. Structure and specificity of T cell receptors expressed by poten-tially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest. 1995;95:531–41.
   Google Scholar
• Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol. 1967;13:269–88.
   PubMed Web of Science ®Google Scholar
• Distler JHW, Pisetsky DS, Huber LC, Kalden JR, Gay S, Distler 0. Microparticles as regulators of inflammation. Arthritis Rheum. 2005;52:3337–48.
   PubMed Web of Science ®Google Scholar
• Fritzsching B, Schwer B, Kartenbeck J, Pedal A, Horejsi V, Ott M et al. Release and intercellular transfer of CD81 via micro-particles. J Immunol. 2002;169:5531–7.
   PubMed Web of Science ®Google Scholar
• Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102:136–44.
   PubMed Web of Science ®Google Scholar
• Mack M, Kleinschmidt A, Bruhl H, Klier C, Nelson PJ, Cihak J. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med. 2000;6:769–75.
   PubMed Web of Science ®Google Scholar
• Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem. 1991;266:17261–8.
   PubMed Web of Science ®Google Scholar
• Hoffman M, Monroe DM, Roberts HR. Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. Thromb Haemost. 1992;68:74–8.
   Google Scholar
• Michelson AD, Rajasekhar D, Bednarek FJ, Barnard MR. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults. Thromb Haemost. 2000;84:689–94.
   PubMed Web of Science ®Google Scholar
• Sims PJ, Wiedmer T, Esmon CT, Weiss JH, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem. 1989;264:17049–57.
   Google Scholar
• Vallar L, Regnault V, Latger-Cannard V, Lecompte T. Beta 2-glycoprotein I binding to platelet microparticle membrane spe-cifically reduces immunoreactivity of glycoproteins Thromb Haemost. 2001;85: 314–219.
   Google Scholar
• Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000;95:930–5.
   PubMed Web of Science ®Google Scholar
• Jimenez JJ, Jy W, Mauro LM, Horstman LL, Yeon S, Ahn WH. Elevated endothelial microparticles in thrombotic thrombocyto-penic purpura: findings from brain and microvascular cell culture and patients with active disease. Br J Haematol. 2001;112:81–90.
   PubMed Web of Science ®Google Scholar
• Shet AS, Aras 0, Gupta K, Hass MJ, Rausch DJ, Saba N et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood. 2003;102:2678–83.
   Google Scholar
• Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC. Cell-derived microparticles generated in patients during cardiopul-monary bypass are highly procoagulant. Circulation. 1997;96:3534–41.
   Google Scholar
• Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL et al. High levels of circulating endothelial mi-croparticles in patients with acute coronary syndromes. Am Heart J. 2003;145:962–70.
   PubMed Web of Science ®Google Scholar
• Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E et al. Elevation of endothelial microparticles, platelets, and leu-kocyte activation in patients with venous thromboembolism. J Am Coll Cardiol. 2005;45:1467–71.
   PubMed Web of Science ®Google Scholar
• Hughes M, Hayward CP, Warkentin TE, Horsewood P, Chome-yko KA, Kelton JG. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood. 2000;96:188–94.
   Google Scholar
• Simak J, Holada K, Risitano AM, Zivny JH, Young NS, Vostal JG. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2004;125:804–13.
   PubMed Web of Science ®Google Scholar
• Brogan PA, Shan V, Brachet C, Hamden A, Mant D, Klein N et al. Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum. 2004;50:927–36.
   PubMed Web of Science ®Google Scholar
• Walenga JM, Jeske WP, Messmore HL. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. J Thromb 'Thrombolysis. 2000;10 Suppl 1:13–20.
   PubMedGoogle Scholar
• Baj-Kryworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, Kijowski J et al. Platelet-derived microparticles stimulate pro-liferation, survival, adhesion and chemotaxis of hematopoietic cells. Exp Hematol. 2002;30:450–9.
   PubMed Web of Science ®Google Scholar
• Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood. 2000;95:1317–23.
   Google Scholar
• Barry OP, Pratico D, Lawson JA, Fitzgerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest. 1997;99:2118–27.
   PubMed Web of Science ®Google Scholar
• Mackenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Suprenant A. Rapid secretion of interleukin-1/3 by microvesicle shedding. Immunity 2001;15: 825–35.
   Google Scholar
• Distler JH, Huber LC, Reich CF III, Gay S, Distler 0, Pisetsky DS. The release of microparticles by apoptotic cells and their effects on macrophages. Apoptosis. 2005;4:731–41.
   Google Scholar
• Martinez MC, Tesse A, Zobairi F, Andrianstsitohaina R. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol. 2005;288:1004–9.
   Web of Science ®Google Scholar
• Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999;30:111–45.
   PubMed Web of Science ®Google Scholar
• Piccin A, Murphy W, Smith 0. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007;21: 157–71.
   Google Scholar
• Butikofer P, Kuypers FA, Xu CM, Chiu DT, Lubin B. Enrich-ment of two glycosyl-phosphatidylinositol-anchored proteins, acetylcholinesterase and decay accelerating factor, in vesicles released from human red blood cells. Blood. 1989;74:1481–5.
   Google Scholar
• Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation. 1999;99:348–53.
   PubMed Web of Science ®Google Scholar
• Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion. 2006;46:1199–209.
   PubMed Web of Science ®Google Scholar
• Minagar A, Jy W, Jimenez JJ, Sheremata WA, Maura LM, Mao WW et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology. 2001;56:1319–24.
   PubMed Web of Science ®Google Scholar
• Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum. 2002;46:1498–503.
   Google Scholar
• Berckmans RJ, Nieuwland R, Tak PP, Boing AN, Romijn FP, Kraan MC et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum. 2002;46:2857–66.
   PubMed Web of Science ®Google Scholar
• Distler JH, Jungel A, Huber LC, Seemayer CA, Reich CF 3rd, Gay RE et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA. 2005;102:2892–7.
   Google Scholar
• Joseph JE, Harrison P, Mackie LT, Isenberg DA, Machin SJ. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol. 2001;115:451–9.
   Google Scholar
• Jy W, Tiede M, Bidot CG, Horstman LL, Jimenez JJ, Chirinos J, et al. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid anti-bodies. Thromb Res 2007;121(3):319–25.
   PubMed Web of Science ®Google Scholar
• Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid antibody syndrome. Thromb Haemost. 2004;91:667–73.
   PubMed Web of Science ®Google Scholar
• Pereira J, Alfaro G, Goycoolea M, Quiroga T, Ocqueteau M, Massardo L, et al. Circulating platelet-derived microparticles in systemic lupus erythematosus: association with increased thrombin generation and procoagulant state. Thromb Haemost. 2006;95:94–9.
   PubMed Web of Science ®Google Scholar